

## **Integration of liquid biopsies into molecular tumor boards**

Ellen Heitzer<sup>1</sup>

<sup>1</sup>Institute of Human Genetics, Medical University of Graz

Comprehensive molecular tumor profiling provides a deeper understanding of the molecular basis of a tumor and can help to tailor treatment for individual patients. However, targeted therapies inevitably lead to genetic tumor evolution and selection of resistant subclones, which is why in addition to tissue analysis liquid biopsy is increasingly used to detect the occurrence of resistance mutations as early as possible, to monitor the response to therapy and to stratify the therapeutic procedure. Therefore, liquid biopsies are increasingly integrated into molecular tumor boards to support the therapy selection in advanced cancer patients. However, with increasing numbers of genes analyzed, the results are not always straightforward and may be challenging to interpret and explain. Question on how to deal with low-level variants, incidental findings of germline mutations in cancer predisposition genes, clonal hematopoiesis or a negative ctDNA result still remain unanswered. In this talk, various clinical scenarios and experiences from liquid profiling within the framework of a molecular tumor board will be discussed.